Connect with us

Markets & Industry

Psychedelics summit sees launch of industry Ethics Council

A new Ethics Council was launched at the Inaugural Summit of The World’s Leaders in Psychedelics that will work to guide industry standards and best practices.



MDMA feasibility study completed by Awakn
Photo by Markus Winkler on Unsplash

A new Ethics Council was launched at the Inaugural Summit of The World’s Leaders in Psychedelics that will work to guide industry standards and best practices.

Experts involved in the Council include Paul Stamets, Rick Doblin, Pam Kryskow, Amanda Feilding and more.

Beckley Waves, the first venture studio explicitly formed to build and invest in the thriving psychedelic ecosystem and advance mental health and well-being, announced the formation of the Council at its inaugural Summit meeting led by Amanda Feilding, founder and executive director of the Beckley Foundation.

Beckley Waves has stated that the topics and issues addressed by the council included:

  • Maintaining an emphasis on sustainable working practices and equitable access.
  • Balancing company expansion with safety, reciprocity with indigenous cultures and local communities.
  • Ongoing scientific research and ethical IP strategies. 
See also  ARC: an ethical framework for the delivery of psychedelic therapy

Amanda Feilding stated: “With this council of advisors and experts, we have access to a great resource that will enable Beckley Waves to expand upon our established foundation and strengthen our capabilities and offerings across this nascent sector.

“Drawing upon their knowledge, experience, and insight has been very valuable as we continue to help shape industry standards and best practices that will enable safe and equitable access to these transformative tools and programmes.”

Others announced as members of the Council include experts from within the psychedelic sector such as Dr Dingle Spence, who is also a lead facilitator at Beckley Retreats, Dr Gita Vaid, and Dr Pamela Kryskow, as well as mission-focused philanthropists, such as Sean Lennon, and Stephen Apkon and Marcina Hale of Reconsider.

Rock Feilding-Mellen and Daniel Love, co-founders at Beckley Waves, Neil Markey, co-founder at Beckley Retreats, and Cosmo Feilding-Mellen, co-founder at the leading psychedelic drug development company Beckley Psytech, were also named as initial members and were in attendance to facilitate the discussions about how to balance mission-driven and sustainable growth and wider public benefits. Specifically, around topics such as equitable access to psychedelic-assisted therapies. 

Many more leaders with expertise in specific fields will be invited to join the council as it grows and develops its agenda.

“These leaders have been laying the foundations of the current renaissance for decades, and we’re just now beginning to see the widespread public interest in and demand for transformative capabilities of psychedelics,” said Rock Feilding-Mellen, co-founder and Managing Partner of Beckley Waves. 

“By gathering these leaders and other renowned experts in psychedelic ethics, we are making a conscious effort to ensure that our continued expansion and growth occur sustainability and ethically and to check that our shared mission stays front and centre of everything we do.”

As interest in and demand for access to guided psychedelic experiences and therapies continues to grow – much of it based on the scientific research that the Beckley Foundation initiated over the last 25 years – Beckley Waves has realized that there is now as great a need to think about safe and responsible access and care delivery as there is for more ground-breaking research into other potential benefits of expanded states of consciousness.

“There is still so much work needed to ensure that the people who need access to psychedelic-assisted therapy can get it lawfully and affordably. I am thrilled to be witnessing a new generation of pioneers ready to pick up and carry on the torch,” added Feilding.

“It has been heartening to see how in recent years, more people are willing to listen to what the science is telling us about the powerfully beneficial potential of these compounds.”

Beckley Waves highlights that demand and expectations for the psychedelics industry are growing rapidly. With that growth comes a responsibility to ensure that the industry is held to a high standard of ethical and sustainable practices. 

The organisation working to help foster a flourishing psychedelic industry, harnessing Amanda Feilding’s historic legacy to pave the way for the continued psychedelic renaissance.

“While the psychedelics industry is in its infancy, these compounds and practices have been used for millennia by Indigenous peoples. As we look to set the standards for industry best practices, we must look to modern science and ancient wisdom,” said Neil Markey, Co-founder, and CEO at Beckley Retreats. 

“We are committed to a process of engagement rooted in listening and discourse — collaborating with those who have been paving the way in the conversation around ethics and in close partnership with the communities where we operate. We hope that others will join us in working to these standards.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more



Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine



Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Markets & Industry

Short Wave Pharma: innovating eating disorder care with psychedelics



Short Wave Pharma: innovating eating disorder care psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity. 

See also  Psych Capital completes acquisition of Short Wave Pharma

The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.

“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID. 

“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.

“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”

The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain. 

The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability. 

“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern. 

The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place. 

Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.

Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.

Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences. 

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study. 

“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process. 

“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.  

“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”

Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.

Continue Reading